SCHEMBL13622707

SCHEMBL13622707

N#Cc1cc(F)c(Cl)nc1N1CCC(CC(=O)O)CC1

nearest known ligand 0.46

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ FFAR4 Q5NUL3 16/20 0.45
▸ KHK P50053 1/20 0.41
▸ PDE4B Q07343 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL1025115 0.95 FFAR4 (0.44) FFAR4KHK
SCHEMBL1025117 0.84 ALDH1A1 (0.36) FFAR4KHK
SCHEMBL13670106 0.82 FFAR4 (0.46) FFAR4
SCHEMBL13622690 0.76 HRH4 (0.51) FFAR4KHKPDE4B
Trifluoroacetic Acid SCHEMBL1022986 0.73 FFAR4 (0.48) FFAR4KHKPDE4B
SCHEMBL3934955 0.73 P2RY12 (0.63) —
SCHEMBL13622633 0.71 KDM4E (0.66) FFAR4PDE4B
SCHEMBL13622692 0.70 ALDH1A1 (0.67) FFAR4KHK
Trifluoroacetic Acid SCHEMBL1023728 0.69 KDM4E (0.58) FFAR4
SCHEMBL13622664 0.69 FFAR4 (0.56) FFAR4PDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-8871753-B2 Macrocyclic compounds and their use as kinase inhibitors INCYTE CORPORATION (US) 2014-10-28 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-11-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286778-A1 MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS JAK2, JAK1, ALK FFAR4 2075/4885KHK 2042/4885PDE4B 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback